Life or Death: P53-induced Apoptosis Requires DNA Binding Cooperativity

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2010 Oct 16

PMID 20948308

Citations 28

Authors

Katharina Schlereth

Joel P Charles

Anne C Bretz

Thorsten Stiewe

Affiliations

Soon will be listed here.

Abstract

The tumor suppressor p53 provides exquisite protection from cancer by balancing cell survival and death in response to stress. Sustained stress or irreparable damage trigger p53's killer functions to permanently eliminate genetically-altered cells as a potential source of cancer. To prevent the unnecessary loss of cells that could cause premature aging as a result of stem cell attrition, the killer functions of p53 are tightly regulated and balanced against protector functions that promote damage repair and support survival in response to low stress or mild damage. In molecular terms these p53-based cell fate decisions involve protein interactions with cofactors and modifying enzymes, which modulate the activation of distinct sets of p53 target genes. In addition, we demonstrate that part of this regulation occurs at the level of DNA binding. We show that the killer function of p53 requires the four DNA binding domains within the p53 tetramer to interact with one another. These intermolecular interactions enable cooperative binding of p53 to less perfect response elements in the genome, which are present in many target genes essential for apoptosis. Modulating p53 interactions within the tetramer could therefore present a novel promising strategy to fine-tune p53-based cell fate decisions.

Citing Articles

Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer.

Kolodziejska R, Tafelska-Kaczmarek A, Pawluk M, Sergot K, Pisarska L, Wozniak A Curr Issues Mol Biol. 2024; 46(7):7668-7685.

PMID: 39057095 PMC: 11275341. DOI: 10.3390/cimb46070454.

Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results.

Trencsenyi G, Csikos C, Kepes Z Int J Mol Sci. 2024; 25(1).

PMID: 38203834 PMC: 10779852. DOI: 10.3390/ijms25010664.

Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy.

Timofeev O, Stiewe T Cancers (Basel). 2021; 13(10).

PMID: 34067731 PMC: 8155944. DOI: 10.3390/cancers13102422.

Salmonella enterica serovar Typhimurium inhibits the innate immune response and promotes apoptosis in a ribosomal/TRP53-dependent manner in swine neutrophils.

Huang T, Jiang C, Yang M, Xiao H, Huang X, Wu L Vet Res. 2020; 51(1):105.

PMID: 32854785 PMC: 7450969. DOI: 10.1186/s13567-020-00828-3.

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells.

Cao N, Lu Y, Liu J, Cai F, Xu H, Chen J Front Pharmacol. 2020; 11:1094.

PMID: 32792943 PMC: 7387512. DOI: 10.3389/fphar.2020.01094.

References

Le Cam L, Linares L, Paul C, Julien E, Lacroix M, Hatchi E . E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell. 2006; 127(4):775-88. DOI: 10.1016/j.cell.2006.09.031. View

Vaseva A, Marchenko N, Moll U . The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle. 2009; 8(11):1711-9. PMC: 2823264. DOI: 10.4161/cc.8.11.8596. View

Korotchkina L, Demidenko Z, Gudkov A, Blagosklonny M . Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle. 2009; 8(22):3777-81. DOI: 10.4161/cc.8.22.10121. View

Karpova T, Kim M, Spriet C, Nalley K, Stasevich T, Kherrouche Z . Concurrent fast and slow cycling of a transcriptional activator at an endogenous promoter. Science. 2008; 319(5862):466-9. DOI: 10.1126/science.1150559. View

Blattner C . Regulation of p53: the next generation. Cell Cycle. 2008; 7(20):3149-53. DOI: 10.4161/cc.7.20.6921. View

Smeenk L, van Heeringen S, Koeppel M, van Driel M, Bartels S, Akkers R . Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res. 2008; 36(11):3639-54. PMC: 2441782. DOI: 10.1093/nar/gkn232. View

Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran T . Structural basis of DNA recognition by p53 tetramers. Mol Cell. 2006; 22(6):741-753. DOI: 10.1016/j.molcel.2006.05.015. View

Chen X, Ko L, Jayaraman L, Prives C . p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 1996; 10(19):2438-51. DOI: 10.1101/gad.10.19.2438. View

Hager G, McNally J, Misteli T . Transcription dynamics. Mol Cell. 2009; 35(6):741-53. PMC: 6326382. DOI: 10.1016/j.molcel.2009.09.005. View

10.

Wei C, Wu Q, Vega V, Chiu K, Ng P, Zhang T . A global map of p53 transcription-factor binding sites in the human genome. Cell. 2006; 124(1):207-19. DOI: 10.1016/j.cell.2005.10.043. View

11.

Funk W, Pak D, Karas R, Wright W, Shay J . A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol. 1992; 12(6):2866-71. PMC: 364481. DOI: 10.1128/mcb.12.6.2866-2871.1992. View

12.

OConnor D, Bergamaschi D, Trigiante G, Hsieh J, Zhong S, Campargue I . ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001; 8(4):781-94. DOI: 10.1016/s1097-2765(01)00367-7. View

13.

Levine A, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-58. PMC: 2771725. DOI: 10.1038/nrc2723. View

14.

Madhumalar A, Jun L, Lane D, Verma C . Dimerization of the core domain of the p53 family: a computational study. Cell Cycle. 2008; 8(1):137-48. DOI: 10.4161/cc.8.1.7530. View

15.

Frebourg T, Kassel J, Lam K, Gryka M, Barbier N, Andersen T . Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci U S A. 1992; 89(14):6413-7. PMC: 49511. DOI: 10.1073/pnas.89.14.6413. View

16.

Tang Y, Luo J, Zhang W, Gu W . Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell. 2006; 24(6):827-39. DOI: 10.1016/j.molcel.2006.11.021. View

17.

Horvath M, Wang X, Resnick M, Bell D . Divergent evolution of human p53 binding sites: cell cycle versus apoptosis. PLoS Genet. 2007; 3(7):e127. PMC: 1934401. DOI: 10.1371/journal.pgen.0030127. View

18.

Knights C, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A . Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol. 2006; 173(4):533-44. PMC: 2063863. DOI: 10.1083/jcb.200512059. View

19.

Perfettini J, Castedo M, Nardacci R, Ciccosanti F, Boya P, Roumier T . Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med. 2005; 201(2):279-89. PMC: 2212781. DOI: 10.1084/jem.20041502. View

20.

Aylon Y, Oren M . Living with p53, dying of p53. Cell. 2007; 130(4):597-600. DOI: 10.1016/j.cell.2007.08.005. View